X

Drug Profile

Peptide G

Alternative Names: Antagonist G; PTL 68001; PTL 68300B

Latest Information Update: 30 May 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cancer Research Technology
Class Antineoplastics
Mechanism of Action Substance P inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Colorectal cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

21 Feb 2002 A phase I study has been added to the Cancer pharmacokinetics and adverse events sections
30 Oct 2000 A phase I study has been added to the Cancer adverse events section
06 Oct 1998 A clinical study has been added to the adverse events section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com